Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

Core Insights - Vericel Corporation will participate in a fireside chat at the Truist Securities MedTech Conference on June 17, 2025, at 9:20 a.m. ET [1] Company Overview - Vericel Corporation is a leader in advanced therapies for sports medicine and severe burn care markets, combining biological innovations with medical technologies [2] - The company markets three products in the United States: - MACI, an autologous cellularized scaffold for repairing full-thickness cartilage defects in the knee [2] - Epicel, a permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [2] - NexoBrid, a biological orphan product for eschar removal in burn patients, for which Vericel holds exclusive North American rights [2]